XRCC1: A Non-Coding RNA Molecule as A Cancer Drug Target and Biomarker

Target Name: XRCC1

NCBI ID: G7515

XRCC1

XRCC1: A Non-Coding RNA Molecule as A Cancer Drug Target and Biomarker

XRCC1 (SCAR26) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) in the field of cancer. XRCC1 has been shown to play a role in the development and progression of various types of cancer, including lung, breast, and ovarian cancer.

XRCC1 is a part of the X chromosome, which is one of the two X chromosomes that a person inherits from each parent. The X chromosome is responsible for the development and maintenance of the body's cells, as well as the transmission of genetic information from one generation to the next.

Studies have shown that changes in the expression of XRCC1 can be associated with the development of cancer. For example, researchers have found that XRCC1 expression is often elevated in cancer cells, and that inhibiting XRCC1 activity has been shown to be effective in inhibiting the growth and spread of cancer cells.

In addition to its potential as a drug target, XRCC1 is also being investigated as a potential biomarker for cancer. The ability to monitor and track the expression of XRCC1 in cancer cells could be used to develop more accurate and effective diagnoses of cancer, as well as to monitor the effectiveness of different treatments.

One of the challenges in studying XRCC1 as a drug target is its complex structure. XRCC1 is a non-coding RNA molecule, which means that it does not have a defined sequence of amino acids. This makes it difficult to predict how a particular variant of XRCC1 will interact with DNA and how it will be able to cause disease.

However, researchers have been able to use computer simulations and other techniques to study the structure and function of XRCC1. These studies have led to some insights into the role of XRCC1 in cancer development and progression.

One of the key features of XRCC1 is its ability to interact with the transcription factor p53. p53 is a protein that plays a critical role in regulating the expression of genes in the cell. genes that are involved in cell growth, division, and apoptosis (programmed cell death).

In cancer cells, the activity of p53 is often disrupted, which allows XRCC1 to accumulate and contribute to the development of cancer. Researchers have also shown that XRCC1 can inhibit the activity of p53, which would normally help to prevent the growth and spread of cancer..

Another study has shown that XRCC1 can also interact with the protein tyrosine kinase (TK) to regulate the activity of genes involved in cell growth and differentiation.

In conclusion, XRCC1 is a promising drug target and biomarker for cancer. Its complex structure and interactions with important transcription factors and proteins make it difficult to study, but these challenges are being addressed by ongoing research. Further research is needed to fully understand the role of XRCC1 in cancer development and progression.

Protein Name: X-ray Repair Cross Complementing 1

Functions: Scaffold protein involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes (PubMed:11163244, PubMed:28002403). Negatively regulates ADP-ribosyltransferase activity of PARP1 during base-excision repair in order to prevent excessive PARP1 activity (PubMed:34102106, PubMed:34811483, PubMed:28002403). Recognizes and binds poly-ADP-ribose chains: specifically binds auto-poly-ADP-ribosylated PARP1, limiting its activity (PubMed:14500814, PubMed:34102106, PubMed:34811483)

The "XRCC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XRCC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets